Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.
Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.